文献速递糖尿病肥胖与代谢综合征

首次检测HbA1c定义的糖尿病前期较糖尿病范围HbA1c预测更高心血管风险:全国登记队列研究

Prediabetes Defined by First Measured HbA1c Predicts Higher Cardiovascular Risk Compared With HbA1c in the Diabetes Range: A Cohort Study of Nationwide Registries.
PubMed 文献 · Diabetes Care · 2021-10-21

基于丹麦全国登记数据,2011至2017年首次HbA1c在40-51 mmol/mol(5.8-6.8%)的326,305例患者中,排除既往疾病后84,678例随访12个月。Cox回归显示主要不良心血管事件(MACE)与全因死亡风险随HbA1c升高至47 mmol/mol(6.5%)逐渐增加,HbA1c 46-47 mmol/mol者较40-41 mmol/mol者MACE风险更高,而48-49 mmol/mol者风险反而较低。结论提示糖尿病前期、尤其接近诊断阈值者心血管风险最高,需加强心血管危险因素管理。

要点

  • HbA1c升至47 mmol/mol(6.5%)前,MACE与全因死亡风险随HbA1c升高逐渐增加。
  • HbA1c 46-47 mmol/mol者MACE的HR为2.21(95%CI 1.67-2.92),高于40-41 mmol/mol者。
  • HbA1c 46-47 mmol/mol者启动降糖等药物治疗显著少于48-49 mmol/mol者。

核心结论

  • 在HbA1c筛查糖尿病人群中,MACE与全因死亡风险最高见于HbA1c略低于糖尿病诊断阈值者。
  • 结果提示对糖尿病前期患者应加强心血管危险因素的治疗关注。

研究设计与样本

  • 基于丹麦全国登记数据库的队列研究。
  • 2011至2017年首次HbA1c 40-51 mmol/mol(5.8-6.8%)者326,305例,排除既往疾病后84,678例随访12个月。
  • 采用Cox回归估计MACE风险比与标准化绝对风险,用累积发病率分析药物启动。

主要发现

  • 12个月MACE与全因死亡风险随HbA1c升高至47 mmol/mol(6.5%)逐渐增加。
  • HbA1c 46-47 mmol/mol(6.4-6.5%)较40-41 mmol/mol(5.8-5.9%)者MACE标准化绝对风险高0.79%(95%CI 0.33-1.24),HR 2.21(95%CI 1.67-2.92)。
  • HbA1c 48-49 mmol/mol(6.5-6.6%)者MACE绝对风险低0.09%(95%CI -0.35至0.52),HR 1.33(95%CI 0.87-2.05)。
  • HbA1c 46-47 mmol/mol者启动药物治疗显著低于48-49 mmol/mol者。

临床怎么用

  • 对HbA1c处于糖尿病前期、尤其接近6.5%者,应重视并加强心血管危险因素管理。
  • 识别HbA1c 46-47 mmol/mol人群可能被低估的心血管风险与治疗不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the risk of major adverse cardiovascular events (MACE), all-cause mortality, and initiation of medical treatment in subjects with prediabetes according to first-time measured HbA1c. RESEARCH DESIGN AND METHODS: Through registry databases, we identified 326,305 Danish patients with a first HbA1c between 40 and 51 mmol/mol (5.8-6.8%) from 2011 to 2017. After exclusion of patients with prior disease, 84,678 patients were followed 12 months after first HbA1c measurement. Cox regression models were used to estimate hazard ratios (HRs) of MACE and standardized absolute risks. Cumulative incidences were used to analyze initiation of glucose-lowering, antihypertensive, cholesterol-lowering, and antithrombotic medication. RESULTS: The 12-month risk of MACE and all-cause mortality increased gradually with increasing HbA1c until 47 mmol/mol (6.5%). In comparisons of subjects with HbA1c 40-41 mmol/mol (5.8-5.9%), subjects with HbA1c 46-47 mmol/mol (6.4-6.5%) had a 0.79% (95% CI 0.33-1.24) higher standardized absolute risk and an HR of 2.21 (95% CI 1.67-2.92) of MACE. Patients with HbA1c 48-49 mmol/mol (6.5-6.6%) had a 0.09% (95% CI -0.35 to 0.52) lower absolute risk and an HR of 1.33 (95% CI 0.87-2.05) of MACE. Initiation of medication was significantly lower among patients with HbA1c of 46-47 mmol/mol (6.4-6.5%) than among patients with HbA1c of 48-49 mmol/mol (6.5-6.6%). CONCLUSIONS: In the Danish population screened for diabetes with HbA1c, the highest risk of MACE and all-cause mortality was found in subjects with HbA1c just below the diagnostic threshold for diabetes. Our results highlight the need for increased focus on the treatment of cardiovascular risk factors for subjects with prediabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Yahyavi SK, Snorgaard O, Knop FK, et al. Prediabetes Defined by First Measured HbA1c Predicts Higher Cardiovascular Risk Compared With HbA1c in the Diabetes Range: A Cohort Study of Nationwide Registries. Diabetes Care. 2021. PMID: 34675054. doi:10.2337/dc21-1062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。